NMIL 12 1

Drug Profile

NMIL 12 1

Alternative Names: HemaMax; NM-IL-12; NMIL12-1; Recombinant-human-interleukin-12 - Neumedicines; Recombinant-interleukin-12 - Neumedicines; rHu-IL12; rHuIL-12 – Neumedicines

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neumedicines
  • Class Interleukins; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Immunostimulants; Interferon gamma stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute radiation syndrome; Cutaneous T cell lymphoma; Wound infections
  • Preclinical Acute myeloid leukaemia; Malignant melanoma; Solid tumours
  • No development reported Pancytopenia

Most Recent Events

  • 03 Dec 2016 Adverse events, efficacy, pharmacodynamics and pharmacokinetics data presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 03 Dec 2016 Neumedicines plans a phase IIB trial for Cutaneous T-cell lymphoma
  • 18 Jul 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top